{"id":"W4385702649","doi":"10.1097/01.hs9.0000975280.98608.35","title":"PB2129: THE MODAKAFUSP ALFA IINNOVATE CLINICAL DEVELOPMENT PROGRAM: RATIONALE AND DESIGN OF 3 PHASE 1/2 TRIALS OF AN INNATE IMMUNITY ENHANCER FOR MULTIPLE MYELOMA (MM)","year":2023,"lang":"en","type":"article","venue":"HemaSphere","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"McMaster University","funders":"","keywords":"Daratumumab; CD38; Multiple myeloma; Medicine; Monoclonal antibody; Innate immune system; Acquired immune system; Immunology; Cancer research; Immune system; Antibody; Biology; Stem cell; Cell biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01028827,0.001217862,0.001422748,0.0006747385,0.000654613,0.001599297,0.001534624,0.002145305,0.005665342],"category_scores_gemma":[0.002400163,0.000533018,0.001361286,0.0005901514,0.0009866412,0.0009420706,0.00085404,0.004112781,0.001794428],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001686161,"about_ca_system_score_gemma":0.00679785,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009128855,"about_ca_topic_score_gemma":0.003246101,"domain_scores_codex":[0.997997,0.001273296,0.00007479984,0.0001659958,0.0002146999,0.0002741184],"domain_scores_gemma":[0.9984907,0.0002394131,0.0002523784,0.0001179696,0.0002325713,0.0006670097],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.303582,0.03596197,0.008559069,0.003907797,0.001354514,0.0004263236,0.0006068344,0.006656185,0.07189944,0.007991402,0.02719552,0.5318589],"study_design_scores_gemma":[0.4510221,0.3970736,0.01200505,0.000945931,0.001248232,0.0006278582,0.0001295409,0.003669372,0.02373866,0.003167839,0.1062889,0.00008302981],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"protocol","genre_scores_codex":[0.6943885,0.03524892,0.02550173,0.01087924,0.00160981,0.180004,0.0103213,0.001010698,0.04103578],"genre_scores_gemma":[0.7485044,0.01874272,0.0758993,0.008474098,0.001219882,0.1143504,0.009803835,0.0003458043,0.02265955],"genre_candidate":"protocol","genre_consensus":null,"teacher_disagreement_score":0.01028827,"threshold_uncertainty_score":0.05441022,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3024710832364378,"score_gpt":0.4907221087897801,"score_spread":0.1882510255533422,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}